What You Should Know:
- The Funding: Amperos Health has closed a $16M Series A funding round led by Bessemer Venture Partners, with participation from Uncork Capital and Neo. This follows a $4.2M seed round in June 2025.
- The Core Technology: Amperos has launched the industry’s first AI-native, end-to-end denial management platform. Unlike fragmented tools that only draft appeal letters or offer predictive scoring, Amperos uses agentic AI (state-of-the-art LLMs with computer and voice capabilities) to independently navigate payer portals, call insurers, and submit corrected claims.
- The Human-in-the-Loop: While the AI handles end-to-end automation, a dedicated team of Amperos subject matter experts provides oversight and judgment for highly complex, difficult-to-recover claims.
- The Hard ROI: The platform resolves denials five times faster than traditional methods. Customers are seeing up to 50% lower costs than traditional outsourced vendors, while recovering over 20% more revenue per claim. To date, Amperos has recovered nearly $700 million annually across 3,000 clinical locations.
Fixing a Broken Revenue Cycle
In 2024, approximately 12% of healthcare claims were denied, resulting in a $262B loss for providers. Traditional recovery efforts are often hindered by chronic understaffing and high turnover rates within revenue cycle management (RCM) teams. Amperos addresses these challenges by using proprietary LLMs to manage the full lifecycle of a denial, including:
- Automated Insurance Follow-Up: Handling portal navigation and calls to insurers without human intervention.
- End-to-End Resolution: Submitting corrected claims, medical records, and drafting complex appeals.
- Continuous Learning: Benchmarking AI performance against human specialists to refine strategies as payer behaviors change.
Measurable Financial Relief
Unlike point solutions that only automate parts of the process—such as drafting letters—Amperos is capable of working denials end-to-end. Early results demonstrate significant operational improvements:
- Higher Recovery: Claim recovery rates are 20% to 22% higher than traditional outsourced vendors.
- Lower Costs: The cost to collect is reduced by up to 50%.
- Efficiency Gains: Providers have reported resolving denials five times faster and cutting overall denial rates by 70%.
- Proven Scale: The platform already serves over 3,000 clinical locations, recovering nearly $700M annually.
The clinical impact is already being felt on the ground. At DOCS Dermatology, VP of Revenue Cycle Management Valerie DeCaro reported recovering 24% more claims without increasing headcount. By benchmarking outcomes against experienced human coders, Amperos’ AI continuously adapts to changing payer behaviors, ensuring that as insurers deploy their own algorithms to deny care, health systems finally have the firepower to fight back at scale.
Strategic Growth and Workforce Support
The Series A funding will accelerate Amperos’ growth into other RCM workflows and expand its analytics capabilities. By filling gaps in the RCM workforce, the platform allows existing staff to focus on high-complexity claims that require human judgment.
“Complexity in healthcare revenue cycle management should not be the norm, and that’s why our mission at Amperos is to streamline the denial and collections process so providers can focus on what matters most,” said Michal Miernowski, CEO and Co-Founder of Amperos Health.
